The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ
暂无分享,去创建一个
E. Shiuan | Shan Wang | D. Brantley-Sieders | Junya Chen | A. Reynolds | Laura C. Kim | Deanna N. Edwards | Verra M. Ngwa | Jin Chen | Eileen Shiuan | Laura C. Kim | Albert B. Reynolds
[1] J. Norman,et al. Phosphorylation of Rab-coupling protein by LMTK3 controls Rab14-dependent EphA2 trafficking to promote cell:cell repulsion , 2017, Nature Communications.
[2] C. Dang,et al. From Krebs to clinic: glutamine metabolism to cancer therapy , 2016, Nature Reviews Cancer.
[3] J. Loscalzo,et al. Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. , 2016, The Journal of clinical investigation.
[4] K. Garber. Cancer anabolic metabolism inhibitors move into clinic , 2016, Nature Biotechnology.
[5] John M. Asara,et al. Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth , 2016, Nature Cell Biology.
[6] S. Stirdivant,et al. The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer. , 2016, Cancer research.
[7] C. Meisinger,et al. ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types , 2016, Nature Communications.
[8] L. Zhu,et al. Tead and AP1 Coordinate Transcription and Motility. , 2016, Cell reports.
[9] G. Bhanot,et al. Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis , 2016, eLife.
[10] G. Mills,et al. Yes‐associated protein 1 and transcriptional coactivator with PDZ‐binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma , 2016, Hepatology.
[11] A. Rosenwald,et al. A MYC-Driven Change in Mitochondrial Dynamics Limits YAP/TAZ Function in Mammary Epithelial Cells and Breast Cancer. , 2015, Cancer cell.
[12] E. Sahai,et al. Reactivation of p53 by a Cytoskeletal Sensor to Control the Balance Between DNA Damage and Tumor Dissemination , 2015, Journal of the National Cancer Institute.
[13] Antonio Rosato,et al. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth , 2015, Nature Cell Biology.
[14] I. Clay,et al. YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers , 2015, PLoS genetics.
[15] A. McCallion,et al. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. , 2015, The Journal of clinical investigation.
[16] H. Katoh,et al. HGF-induced serine 897 phosphorylation of EphA2 regulates epithelial morphogenesis of MDCK cells in 3D culture , 2015, Journal of Cell Science.
[17] S. Cohen,et al. Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover , 2014, The EMBO journal.
[18] Wenwei Hu,et al. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma , 2014, Oncotarget.
[19] N. Sang,et al. ErbB2 Activation Upregulates Glutaminase 1 Expression Which Promotes Breast Cancer Cell Proliferation , 2014, Journal of cellular biochemistry.
[20] Tao Zhang,et al. Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. , 2014, International journal of clinical and experimental pathology.
[21] Jennifer B Dennison,et al. Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer , 2014, Molecular Cancer Therapeutics.
[22] Y. Zhong,et al. Epigenetic silencing of glutaminase 2 in human liver and colon cancers , 2013, BMC Cancer.
[23] G. Halder,et al. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment , 2013, Nature Reviews Drug Discovery.
[24] Jie Zhou,et al. Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation. , 2013, Biochimica et biophysica acta.
[25] N. Mochizuki,et al. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase , 2013, Oncogene.
[26] Ralph J DeBerardinis,et al. Glutamine and cancer: cell biology, physiology, and clinical opportunities. , 2013, The Journal of clinical investigation.
[27] N. Elvassore,et al. A Mechanical Checkpoint Controls Multicellular Growth through YAP/TAZ Regulation by Actin-Processing Factors , 2013, Cell.
[28] Ying Chen,et al. Activation of SNAT1/SLC38A1 in human breast cancer: correlation with p-Akt overexpression , 2013, BMC Cancer.
[29] W. Jung,et al. Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer. , 2013, Endocrine-related cancer.
[30] David M. Thomas,et al. The Hippo pathway and human cancer , 2013, Nature Reviews Cancer.
[31] Nam‐Gyun Kim,et al. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1 , 2013, Proceedings of the National Academy of Sciences.
[32] S. Lev,et al. VAMP-Associated Protein B (VAPB) Promotes Breast Tumor Growth by Modulation of Akt Activity , 2012, PloS one.
[33] K. Guan,et al. Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). , 2012, Genes & development.
[34] Xiang-Dong Fu,et al. Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling , 2012, Cell.
[35] Raymond K. Auerbach,et al. An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.
[36] I. Pogribny,et al. An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression , 2012, Breast Cancer Research and Treatment.
[37] Q. Ou,et al. Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. , 2012, European journal of cancer.
[38] A. Cassago,et al. Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism , 2012, Proceedings of the National Academy of Sciences.
[39] S. Bicciato,et al. The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.
[40] Dana M. Brantley-Sieders,et al. Eph/Ephrin Profiling in Human Breast Cancer Reveals Significant Associations between Expression Level and Clinical Outcome , 2011, PloS one.
[41] Nicola Elvassore,et al. Role of YAP/TAZ in mechanotransduction , 2011, Nature.
[42] M. Goodman,et al. Potential Biomarker of L-type Amino Acid Transporter 1 in Breast Cancer Progression , 2011, Nuclear medicine and molecular imaging.
[43] Xiaolong Yang,et al. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. , 2011, Cancer research.
[44] S. Lowe,et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma , 2011, Oncogene.
[45] Anirban Datta,et al. A molecular network for de novo generation of the apical surface and lumen , 2010, Nature Cell Biology.
[46] Z. Szallasi,et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.
[47] Zhengyu Zha,et al. The Hippo Tumor Pathway Promotes TAZ Degradation by Phosphorylating a Phosphodegron and Recruiting the SCFβ-TrCP E3 Ligase* , 2010, The Journal of Biological Chemistry.
[48] C. Dang,et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. , 2010, Cancer cell.
[49] C. Thompson,et al. Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.
[50] Elena B. Pasquale,et al. Eph receptors and ephrins in cancer: bidirectional signalling and beyond , 2010, Nature Reviews Cancer.
[51] Michael Hummel,et al. Supplementary Figure 3 , 2010 .
[52] Jennifer L. Cutter,et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. , 2009, Cancer cell.
[53] Michael D. Wilson,et al. ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. , 2009, Methods.
[54] W. Hong,et al. TEADs Mediate Nuclear Retention of TAZ to Promote Oncogenic Transformation* , 2009, Journal of Biological Chemistry.
[55] Zhengyu Zha,et al. TEAD Transcription Factors Mediate the Function of TAZ in Cell Growth and Epithelial-Mesenchymal Transition* , 2009, Journal of Biological Chemistry.
[56] I. Rustenbeck,et al. Triggering and amplification of insulin secretion by dimethyl alpha-ketoglutarate, a membrane permeable alpha-ketoglutarate analogue. , 2009, European journal of pharmacology.
[57] I. Rustenbeck,et al. Triggering and amplification of insulin secretion by dimethyl α-ketoglutarate, a membrane permeable α-ketoglutarate analogue , 2009 .
[58] P. Chiarugi,et al. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. , 2009, Cancer research.
[59] Dana M. Brantley-Sieders,et al. Eph receptors in breast cancer: roles in tumor promotion and tumor suppression , 2008, Breast Cancer Research.
[60] Anthony Mancuso,et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.
[61] Jiandie D. Lin,et al. TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.
[62] Michael Q. Zhang,et al. Combinatorial patterns of histone acetylations and methylations in the human genome , 2008, Nature Genetics.
[63] Dana M. Brantley-Sieders,et al. Identification and Functional Analysis of Phosphorylated Tyrosine Residues within EphA2 Receptor Tyrosine Kinase* , 2008, Journal of Biological Chemistry.
[64] Q. Zeng,et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. , 2008, Cancer research.
[65] H. Kiyonari,et al. Redundant Roles of Tead1 and Tead2 in Notochord Development and the Regulation of Cell Proliferation and Survival , 2008, Molecular and Cellular Biology.
[66] Jin Chen,et al. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism , 2008, Journal of Cell Science.
[67] Dana M. Brantley-Sieders,et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. , 2008, The Journal of clinical investigation.
[68] Li Li,et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. , 2007, Genes & development.
[69] G. Feldmann,et al. Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals , 2007, Cell.
[70] Dustin E. Schones,et al. High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.
[71] Xiaolian Gao,et al. Insights into transcription enhancer factor 1 (TEF-1) activity from the solution structure of the TEA domain , 2006, Proceedings of the National Academy of Sciences.
[72] Jianmin Zhang,et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon , 2006, Proceedings of the National Academy of Sciences.
[73] R. Neve,et al. A conditional feedback loop regulates Ras activity through EphA2. , 2005, Cancer cell.
[74] Andy J. Minn,et al. Genes that mediate breast cancer metastasis to lung , 2005, Nature.
[75] C. Arteaga,et al. Overexpression of HER2 (erbB2) in Human Breast Epithelial Cells Unmasks Transforming Growth Factor β-induced Cell Motility* , 2004, Journal of Biological Chemistry.
[76] M. Hediger,et al. The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects , 2004, Pflügers Archiv.
[77] Dana M. Brantley-Sieders,et al. Increased Malignancy of Neu-Induced Mammary Tumors Overexpressing Active Transforming Growth Factor β1 , 2003, Molecular and Cellular Biology.
[78] Jayanta Debnath,et al. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.
[79] M. Kinch,et al. Regulation of the EphA2 Kinase by the Low Molecular Weight Tyrosine Phosphatase Induces Transformation* , 2002, The Journal of Biological Chemistry.
[80] A. Pozzi,et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo , 2002, Oncogene.
[81] K. Kullander,et al. Mechanisms and functions of eph and ephrin signalling , 2002, Nature Reviews Molecular Cell Biology.
[82] M. DePamphilis,et al. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. , 2001, Genes & development.
[83] M. Yaffe,et al. TAZ: a novel transcriptional co‐activator regulated by interactions with 14‐3‐3 and PDZ domain proteins , 2000, The EMBO journal.
[84] J. Márquez,et al. Identification of two human glutaminase loci and tissue-specific expression of the two related genes , 2000, Mammalian Genome.
[85] J. Schlessinger. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[86] W. Souba,et al. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. , 1999, Physiological genomics.
[87] Yoshiharu Matsuura,et al. Phosphorylation and Activation of Myosin by Rho-associated Kinase (Rho-kinase)* , 1996, The Journal of Biological Chemistry.
[88] V. Ganapathy,et al. Cloning of the Sodium-dependent, Broad-scope, Neutral Amino Acid Transporter Bo from a Human Placental Choriocarcinoma Cell Line* , 1996, The Journal of Biological Chemistry.
[89] Melissa C. Greven,et al. An integrated encyclopedia of DNA elements in the human genome , 2014 .
[90] Jin Chen. Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases. , 2012, Advances in cancer research.
[91] Zhongmei Zhou,et al. TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. , 2012, Carcinogenesis.
[92] K. Guan,et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. , 2011, Genes & development.
[93] Lu Xie,et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. , 2010, Cancer research.
[94] K. Guan,et al. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). , 2010, Genes & development.
[95] D. Raftery,et al. Early detection of recurrent breast cancer using metabolite profiling. , 2010, Cancer research.
[96] Tsung-Cheng Chang,et al. c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2009, Nature.
[97] Dana M. Brantley-Sieders,et al. The receptor tyrosine kinase EphA 2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB 2 signaling , 2007 .
[98] T. Barrette,et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.
[99] J. Schlessinger,et al. Signaling by Receptor Tyrosine Kinases , 1993 .